Prakt. lékáren. 2021; 17(3): e22-e34 [Klin Farmakol Farm. 2021;35(1):12-18]

Pharmacokinetic and pharmacodynamic interactions of antiepileptic drugs

Milan Grundmann1, Ivana Kacířová1, 2
1 Ústav klinické farmakologie, Lékařská fakulta, Ostravská univerzita, Ostrava
2 Oddělení klinické farmakologie, Ústav laboratorní medicíny, Fakultní nemocnice Ostrava

Approximately 30 % of patients with epilepsy are refractory to monotherapy and are invariably prescribed two or more antiepileptic drugs to control seizures. Because of the long-term nature of epilepsy treatment, it is inevitable that patients will be prescribed nonepilepsy drugs to treat comorbidities. Furthermore, patients with epilepsy may use over-the-counter medications. For these reasons, the propensity of drug-drug interactions is high.

Keywords: epilepsy, antiepileptic drugs, interaction, therapeutic drug monitoring.

Published: October 12, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grundmann M, Kacířová I. Pharmacokinetic and pharmacodynamic interactions of antiepileptic drugs. Praktické lékárenství. 2021;17(3):e22-34.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Patel P, Moshé SL. The evolution of the concepts of seizures and epilepsy: What's in a name? Epilepsia Open. 2020 Jan 10; 5(1): 22-35. Go to original source... Go to PubMed...
    2. Landmark CJ, Johannesse SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016 Dec 1; 18(4): 367-383. Go to original source... Go to PubMed...
    3. Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018 Oct; 40(5): 526-548. Go to original source... Go to PubMed...
    4. Rowland A, Miners JO, Mackenzie PI. The UDP‑glucuronosyltransferases: Their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013 Jun; 45(6): 1121-1132. Go to original source... Go to PubMed...
    5. Lesko LJ, Schmidt S. Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther 2012; 92(4): 458-466. Go to original source... Go to PubMed...
    6. Buchthal F, Svensmark O. Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia 1960; 1: 373-384. Go to original source... Go to PubMed...
    7. Grundmann M, Kacířová I. Terapeutické monitorování hladin antiepileptik I. - obecné zásady, "stará" antiepileptika. Klin Farmakol Farm 2016; 30(2): 9-15. Go to original source...
    8. Kořístková B, Grundmann M. Lékové interakce antiepileptik. Část 1. - vzájemné interakce mezi antiepileptiky. Klin Farmakol Farm 2016; 30(4): 19-23. Go to original source...
    9. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord 2014; 16 (4): 409-432. Go to original source... Go to PubMed...
    10. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32: 570-572. Go to original source... Go to PubMed...
    11. Kitada N, Nishiyama Y, Watari M, Kuroda K, Kubo S, Nakata H, Ohnishi N, Yokoyama T. Reductions in plasma phenytoin concentrations during nasogastric enteral feeding in the patients with cerebral infarction. Jpn J TDM 2002; 3: 282-287.
    12. Urashima Y, Urashima K, Ohnishi M, Matsushita K, Suzuki K, Kurachi K, Nishihara M, Katsumata T, Myotoku M, Ikeda K, Hirotani Y. Interaction between phenytoin and enteral nutrients and its influence on gastrointestinal absorption. Pharmazie 2019; 74: 559-562. Go to PubMed...
    13. Nagai K, Omotani S, Shibano M, Kobayashi A, Ito A, Nishimura I, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Effects of semi‑solidification of enteral nutrients on the pharmacokinetic behavior of orally administered carbamazepine in rats. Int J Med Sci. 2019; 16(9): 1283-1286. Go to original source... Go to PubMed...
    14. VandenBerg A, Broadway J. Enteral administration of protein supplement and valproate: A potential pharmacokinetic interaction. Ment Health Clin [Internet]. 2017; 7(1): 10-12. Go to original source... Go to PubMed...
    15. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The Importance of Drug Interactions in Epilepsy Therapy. Epilepsia 2002; 43(4): 365-385. Go to original source... Go to PubMed...
    16. Landmark CJ, Johannessen SI, Patsalos PN. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol. 2020 Mar; 16(3): 227-238. Go to original source... Go to PubMed...
    17. Klomp SD, Manson ML, Guchelaar HJ, Swen JJ. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. J Clin Med. 2020 Sep 7; 9(9): 2890. Go to original source... Go to PubMed...
    18. Verrotti A, Lattanzi S, Brigo F, Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020 Mar; 104(Pt A): 106939. Go to original source... Go to PubMed...
    19. Morano A, Fanella M, Albini M, Cifelli P, Palma E, Giallonardo AT, Di Bonaventura C. Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. Neuropsychiatr Dis Treat. 2020 Feb 7; 16: 381-396. Go to original source... Go to PubMed...
    20. Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016 Apr; 106: 72-86. Go to original source... Go to PubMed...
    21. Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Archives of Toxicology 2020; 94: 3671-3722. Go to original source... Go to PubMed...
    22. Stingl JC, Bartels H, Viviani R, Lehmanna ML, Brockmöller J. Relevance of UDP‑glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Ther. 2014 Jan; 141(1): 92-116. Go to original source... Go to PubMed...
    23. Kacířová I, Grundmann M. Terapeutické monitorování hladin antiepileptik II. - "nová" antiepileptika, speciální skupiny pacientů. Klin Farmakol Farm 2016; 30(2): 16-22. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.